Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

2015450 citationsJournal Article

Authors

Davide Capodanno · University of Catania

Tommaso Gori · Johannes Gutenberg University Mainz

Holger Nef · University of Giessen

Azeem Latib · Vita-Salute San Raffaele University

Julinda Mehilli · Ludwig-Maximilians-Universität München

Maciej Lesiak · Poznan University of Medical Sciences

Giuseppe Caramanno

Abstract

"Real-world" outcomes of BVS showed acceptable rates of TLF at six months, although the rates of early and midterm scaffold thrombosis, mostly clustered within 30 days, were not negligible.

Topics & Keywords

Coronary Interventions and Diagnostics Antiplatelet Therapy and Cardiovascular Diseases Cardiac Valve Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: EuroIntervention

Volume 10, Issue 11, pp. 1144-1153

DOI: 10.4244/eijy14m07_11

Field-Weighted Citation Impact: 108.27